Madrigal turns to RNAi drugs from China to bolster MASH pipeline

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA interference medicines for the common liver condition.

By Kristin Jensen • Feb. 11, 2026

Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill

Shares of Evommune nearly doubled on data suggesting it has a potential threat to Dupixent. Elsewhere, a closely watched narcolepsy drug got an FDA decision date and investors scrutinized Upstream’s asthma results.

By BioPharma Dive staff • Feb. 11, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

FDA refuses to review Moderna’s mRNA flu vaccine

Moderna claimed that the decision, issued by top vaccine regulator Vinay Prasad, was “inconsistent” with prior FDA communications and went against the regulator’s established guidance for flu shots.

By Delilah Alvarado • Feb. 11, 2026

Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug

Shares fell as much as 6% in after-hours trading, a decline one analyst guessed may be because Yeztugo’s trajectory isn’t matching investors’ sky-high hopes.

By Jacob Bell • Feb. 10, 2026

Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study

The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent. 

By Jonathan Gardner • Feb. 10, 2026

Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals

Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that modify immune cells inside the body. 

By Jonathan Gardner • Feb. 9, 2026

Lilly bets again on China drugs; Roche showcases MS data

Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.

By BioPharma Dive staff • Feb. 9, 2026

Takeda, Iambic partner in latest pharma AI push

“The winners over the next five years” will be the companies that “fully integrate” artificial intelligence into drug development, said Takeda research chief Andy Plump.

By Jacob Bell • Feb. 9, 2026

Hengrui, Kailera tout positive results for dual-acting obesity pill

Kailera CEO Ron Renaud claimed the weight loss effects and safety profile observed in the study suggest its therapy could eventually become a “differentiated treatment option” compared to other obesity pills.

By Delilah Alvarado • Feb. 9, 2026

Agomab, SpyGlass bank a combined $350M in biotech IPOs

The two offerings capped off the busiest week for new biotech stock issuances in a year.

By Gwendolyn Wu • Feb. 5, 2026

Generate, an AI-driven Flagship startup, pitches an IPO

The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.

By Kristin Jensen • Feb. 5, 2026

Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings

Eikon’s offering ranks as the largest new biotech stock issuance since Acelyin’s $540 million haul nearly three years ago.

By Gwendolyn Wu • Feb. 4, 2026

Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.

By BioPharma Dive staff • Feb. 4, 2026

FDA launches ‘PreCheck’ program; AstraZeneca, Acadia drugs set back

The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene therapy.

By BioPharma Dive staff • Feb. 3, 2026

GSK walks away from pioneering Wave RNA editing drug

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.

By Ben Fidler • Updated Feb. 2, 2026

Amgen gives up on its once-prized eczema drug

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent. 

By Jonathan Gardner • Jan. 30, 2026

The biopharma industry outlook on 2026: Optimism and tension

A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.

By Ben Fidler • Jan. 29, 2026

Moderna holds a ‘garage sale’; Roche defends obesity drug data

Moderna licensed out a rare disease drug for what an analyst called a “modest” sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit’s PD-1/VEGF blocker got an FDA decision date.

By BioPharma Dive staff • Jan. 29, 2026

Tenpoint wins FDA nod for combination presbyopia eye drop

The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an advance over existing treatments from AbbVie and others.

By Gwendolyn Wu • Jan. 29, 2026

Halozyme buys a biotech startup; Cytokinetics launches heart drug

Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst wrote. Elsewhere, Boehringer dipped into China for a bispecific drug and a trans-Atlantic VC firm restocked.

By BioPharma Dive staff • Jan. 28, 2026

Regenxbio gene therapy trials suspended by FDA over safety worries

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing and a treatment for Hunter syndrome nearing an FDA decision.

By Kristin Jensen • Jan. 28, 2026

FDA lifts hold on an Intellia CRISPR drug trial

Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.

By Delilah Alvarado • Jan. 27, 2026

An immune drug developer raises $50M to finance its eczema drug testing

TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

By Gwendolyn Wu • Jan. 27, 2026

China’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says

The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.

By Ben Fidler • Jan. 26, 2026

Biotech investor Cormorant secures $150M for another SPAC deal

Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.

By Ben Fidler • Jan. 26, 2026